课题基金 / 基金详情

University of Colorado Parkinson's Disease Clinical Research

University of Colorado Parkinson's Disease Clinical Research
科罗拉多大学帕金森病临床研究
批准号:
8601330
负责人:
MAUREEN A LEEHEY
金额:
$10.09万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2014-11-30

项目摘要

项目成果

MAUREEN A LEEHEY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Parkinson's disease (PD) affects at least a half million Americans, and more as our population ages. Symptomatic medications can dramatically improve the lives of patients initially. However, with time disabling and unpredictable motor fluctuations occur, and the disease relentlessly progresses in most to dementia and immobility in the end stages. Therapy that slows progression of disease (neuroprotection) is desperately needed for the many thousands of affected Americans. In an effort to develop neuroprotective therapy the NINDS funded the NIH Exploratory Trials in PD (NET- PD) program, which consists of a Clinical Trials Coordination Center, a Statistical Center and 50 Clinical Sites. To date the NET-PD program has successfully completed four futility trials, is currently conducting a fifth futility trial (pioglitazone), and is in the process of completing a large simple (LSI) Phase III randomized, double-blinded, placebo-controlled clinical trial (creatine). These activities have contributed valuable scientific advances to the PD community. Our site, the University of Colorado Denver (UCD), is one of 50 selected Clinical Sites. The current NET-PD trials are expected to take three more years to complete; this application is a request for funding to complete the trials. Recruitment and retention of subjects at the Clinical Sites will be crucial fo success. The Specific Aims for the UCD site are (1) to complete the LSI study with retention of >85% of subjects and with >75% active in Study and on study drug, and (2) to do so with high adherence to study protocol and regulatory requirements. The UCD site has contributed greatly to the current success of the NET-PD program. For example, in LSI UCD is the fourth highest enrolling site and is the ninth highest in terms of retention of subjects on study drug. Dr. Leehey serves on the NET-PD program's Recruitment & Retention Committee and thus helped develop severally strategies that most sites employ to maximize recruitment and retention. Our site enters data and handles queries in a more reliable and timely fashion than average for all 50 sites. UCD has a number of strengths detailed in this application, including individualized expert care to subjects, which underlie our success and the reason our site is a strong and necessary asset to the NET-PD program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of Colorado Parkinson's Disease Clinical Research Program
  • 批准号:
    7775046
  • 项目类别:
  • 资助金额:
    $11.89万
  • 财政年份:
    2002
  • 负责人:
    MAUREEN A LEEHEY
  • 依托单位:
U Colorado Parkinson's Disease Clinical Research
  • 批准号:
    6546281
  • 项目类别:
  • 资助金额:
    $10.96万
  • 财政年份:
    2002
  • 负责人:
    MAUREEN A LEEHEY
  • 依托单位:
University of Colorado Parkinson's Disease Clinical Research
  • 批准号:
    8461003
  • 项目类别:
  • 资助金额:
    $10.04万
  • 财政年份:
    2002
  • 负责人:
    MAUREEN A LEEHEY
  • 依托单位:
University of Colorado Parkinson's Disease Clinical Research Program
  • 批准号:
    8033813
  • 项目类别:
  • 资助金额:
    $10.66万
  • 财政年份:
    2002
  • 负责人:
    MAUREEN A LEEHEY
  • 依托单位:
海外基金